Airborne develops and sells immune support products including iconic effervescent tablets, new chewable tablets and on-the-go packets, all in a variety of flavors.
The all-cash transaction is done through a combination of Schiff’s new debt facility and cash on its balance sheet.
Schiff Nutrition president and chief executive officer Tarang Amin said the company intends to couple Airborne’s product portfolio with its strong capabilities in science and innovation.
"For example, there has been promising scientific research into the potential relationship between BC30, the proprietary probiotics technology we acquired rights to last year, and supporting the immune system," Amin added.
The transaction is anticipated to become accretive during the first half of 2014.